Real-World Study of Androgen Receptor Pathway Inhibitor Use in Australian Men With Metastatic Hormone-Sensitive Prostate Cancer

What this Trial Is About

This research aims to understand treatment patterns and patient characteristics in adult men with metastatic hormone-sensitive prostate cancer mHSPC in Australia. The focus is on men whose cancer has spread but still responds to hormone therapy. Researchers study how drugs called Androgen Receptor Pathway Inhibitors ARPIsincluding darolutamide, enzalutamide, apalutamide, and abirateroneare used in real-world settings alongside standard hormone treatments. The study looks at existing prescription data collected from two large Australian databases, the Pharmaceutical Benefits Scheme and the NostraData retail pharmacy dataset. It examines the use of ARPIs alone or combined with other treatments like androgen deprivation therapy ADT and chemotherapy with docetaxel. The analysis includes which ARPIs patients receive, whether they are using doublet therapy ARPI ADT or triplet therapy ARPI ADT docetaxel, and how dosages and adherence change over time. Participants are not directly involved since the study uses anonymized prescription records from December 2022 to June 2025. Researchers will measure the number and proportion of patients using each ARPI, demographic details like age and location, adherence to ARPI treatment, and dose changes. These findings will provide insights into real-world treatment use and help improve care for men with mHSPC.

An Observational Study to Learn More About How Medicines That Block Male Hormones Are Used in People With Prostate Cancer in Australia